Low dose alpha-methyl-para-tyrosine (AMPT) in the treatment of dystonia and dyskinesia

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 19, Issue 1, 2007, Pages 65-69

  Ankenman, Ralph ^a,c   Salvatore, Michael F ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b Madison County Hospital   (United States)

^c 306 Whitney Hendrickson Building ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; CLOZAPINE; DOPAMINE; HALOPERIDOL; METIROSINE; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; PROLACTIN; QUETIAPINE; RISPERIDONE; SODIUM; TRIHEXYPHENIDYL; TYROSINE 3 MONOOXYGENASE;

ADOLESCENT; ADULT; AKATHISIA; ANXIETY DISORDER; ARTICLE; CASE REPORT; CRYSTALLURIA; DEPRESSION; DIARRHEA; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DOWN REGULATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; HALLUCINATION; HUMAN; LOW DRUG DOSE; MOTOR DYSFUNCTION; NEUROLEPTIC MALIGNANT SYNDROME; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SIDE EFFECT; SODIUM BLOOD LEVEL; TREATMENT OUTCOME; TREMOR;

EID: 33847103835     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.2007.19.1.65     Document Type: Article

References (25)

1. Sjoerdsma A, Engelman K, Spector S, et al: Inhibition of catacholamine synthesis in man with alpha-methyl-tyrosine, an inhibitor of tyrosine hydroxylase. Lancet 1965; 286:1092-1094
2. Engleman K, Horwitz D, Jequier E, et al: Biochemical and pharmacological effects of A-methyltryosine in man. J Clin Invest 1968; 47:577-594
3. Walinder J, Skott A, Carlsson A, et al: Potentiation by metyrosine of thioridazine effects in chronic schizophrenics: a long-term trial using double-blind crossover technique. Arch Gen Psych 1976; 33:501-505
4. Fahn S: Treatment of tardive dyskinesia: use of dopamine-depleting agents. Clin Neuropharmacol 1983; 6:151-158
5. Lang AE, Masden CD: Alpha methylparatyrosine and tetrabenazine in movement disorders. Clin Neuropharmacol 1982; 5:375-387
6. Burke RE, Fahn S, Mayeaux R, et al: Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington's disease. Neurology 1981; 31:1022-1025
7. Pozuels J: Suppression of craving and withdrawal in humans addicted to narcotics or amphetamines by administration of alpha-methyl-para-tyrosine (AMPT) and 5-butylpicolinic acid (fusaric acid) treatment of narcotic and amphetamine addiction in humans: preliminary report. Cleve Clin Q 1976; 43:89-94
8. Adler CH: Strategies for controlling dystonia: overviews of therapies that may alleviate symptoms. Postgrad Med 2000; 108:151-160
9. Yavich L: Two simultaneously working storage pools of dopamine in mouse caudate and nucleus accumbens. Br J Pharmacol 1996; 119:869-876
10. Feldman RS, Meyer JS, Quenzer LF: Catecholamines, in Principles of Neuropsychopharmacology. Sunderland, Mass, Sinauer Associates, 1997, pp 277-344
11. Kannari K, Tanaka H, Maeda T, et al: Reserpine pretreatment prevents increases in extracellular striatal dopamine following 1-dopa administration in rats with nigrostriatal denervation. J Neurochem 2000; 74:263-269
12. Demser (AMPT), in Physicians Desk Reference. Montdale NJ, Thompson PDR, 2005, p 2036
13. Salvatore MF, Waymire JC, Haycock JW: Depolarization-stimulated catacholamine biosynthesis: involvement of protein kinases and tyrosine hydroxylase phosphorylation sites in situ. J Neurochem 2001; 79:349-360
14. Lindgren N, Xu ZQ, Lindskog M, et al: Regulation of tyrosine hydroxylase activity and phosphorylation at Ser19 and Ser40 via activation of glutamate NMDA receptors in rat striatum. J Neurochem 2000; 74:2470-2477
15. Chalazonitis A, Rice PJ, Zigmond RE: Increased ganglionic tyrosine hydroxylase and dopamine-beta-hydroxylase activities following preganglionic nerve stimulation: role of nicotine receptors. J Pharmacol Exp Ther 1980; 213:139-134
16. Oishi R, Shishido S, Yamori M, et al: Comparison of the effects of eleven histamine H1-receptor antagonists on monoamine turnover in the mouse brain. Naunyn Schmiedebergs Arch Pharmacol 1994; 349:140-144
17. Haycock JW: Multiple signaling pathways in bovine chromaffin cells regulate tyrosine hydroxylase phosphorylation at Ser19, Ser31, and Ser40. Neurochem Res 1993; 18:15-26
18. Zivkovic B, Guidotti A, Revuelta A, et al: Effect of thioridazine, clozapine, and other antipsychotics on the kinetic state of tyrosine hydroxylase and on the turnover rate of dopamine in the striatum and nucleus accumbens. J Pharmacol Exp Ther 1975; 194:37-46
19. Hakannson K, Pozzi L, Usiello A, et al: Regulation of striatal tyrosine hydroxylase phosphorylation by acute and chronic haloperidol. Eur J Neurosci 2004; 20:1108-1112
20. Salvatore MF, Garcia-Espana A, Goldstein M, et al: Stoichiometry of tyrosine hydroxylase phosphorylation in the nigrostriatal and mesolimbic system in vivo: effects of acute haloperidol and related compounds. J Neurochem 2000; 75:225-232
21. Ankenman R: The combination of amantadine and neuroleptics plus time may cure tardive dyskinesia. J Neuropsychiatry 1989; 1:96-97
22. Lopez-Munoz F, Bhatara VS, Alamo C, et al: Historical approach to reserpine discovery and its introduction in psychiatry. Actas Esp Psiquiatr 2004; 32:387-395
23. Goetz CG, Horn S: Tardive dyskinesia, in Movement Disorders: Neurologic Principles and Practice. Edited by Watts RL, Koller WC. New York, McGraw-Hill Medical Publishing, 2004, pp 629-637
24. Bobrovskaya L, Dunkley PR, Dickson PW: Phosphorylation of Ser19 increases both Ser40 phosphorylation and enzyme activity of tyrosine hydroxylase in intact cells. J Neurochem 2004; 90: 857-864
25. Lindgren N, Xu ZQ, Herrera-Marschitz M, et al: Dopamine D2 receptors regulate tyrosine hydroxylase activity and phosphorylation at Ser 40 in rat striatum. Eur J Neurosci 2001; 13:773-780